3-氰基-1,2,4-三氮唑 | 3641-10-9

• 物质功能分类: 医药中间体
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 3-氰基-1,2,4-三氮唑
• 中文别名: 3-腈基-1H-1,2,4-三氮唑；3-氰基-1,2,4-三唑；3-氰基-1,2,4-噻唑
• 英文名称: 1H-1,2,4-triazole-3-carbonitrile
• 英文别名: 3-cyano-1,2,4-triazole；3-cyano-1H-1,2,4-triazole；1,2,4-triazole-3-carbonitrile；3-Cyano-1,2,4-triazol；1H-1,2,4-triazole-5-carbonitrile
• CAS: 3641-10-9
• 化学式: C₃H₂N₄
• mdl: MFCD07366408
• 分子量: 94.0757
• InChiKey: GUQHFZFTGHNVDG-UHFFFAOYSA-N

物化性质

• 熔点：
  185-187°C
• 沸点：
  300.0±25.0 °C(Predicted)
• 密度：
  1.44±0.1 g/cm3(Predicted)
• 溶解度：
  可溶于二甲基亚砜、甲醇

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  7
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  65.4
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险类别码：
  R20/21/22
• 危险品运输编号：
  UN 3276
• 海关编码：
  2933990090
• 安全说明：
  S26,S36/37/39
• WGK Germany：
  3
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-Cyano-1,2,4-triazole
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-Cyano-1,2,4-triazole
CAS number: 3641-10-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C3H2N4
Molecular weight: 94.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途
用于有机合成中间体

用途
作为有机中间体

反应信息

• 作为反应物：
  描述：

  3-氰基-1,2,4-三氮唑 在 sodium methylate 、 氯化铵 作用下， 以 甲醇 为溶剂， 反应 12.0h， 以78.8%的产率得到1H-1,2,4-triazole-3-carboximidamide hydrochloride
  参考文献：
  名称：

  杂芳基取代的二氢嘧啶类化合物及其在药物 中的应用

  摘要：

  本发明涉及一种杂芳基取代的二氢嘧啶类化合物及其作为药物的用途，尤其是作为用于治疗和预防乙型肝炎的药物的应用。具体地说，本发明涉及通式（I）或（Ia）所示的化合物或它们的对映异构体、非对映异构体、水合物、溶剂化物或药学上可接受的盐，其中各变量如说明书所定义。本发明还涉及通式（I）或（Ia）所示的化合物或它们的对映异构体、非对映异构体、水合物、溶剂化物或药学上可接受的盐或其药物组合物的用途，尤其是作为用于治疗和预防乙型肝炎的药物的用途。

  公开号：

  CN103664899B
• 作为产物：
  描述：

  2H-1,2,4-三氮唑-3-甲酰胺 在 吡啶 、 乙酸酐 作用下， 以 1,4-二氧六环 为溶剂， 反应 0.17h， 以72%的产率得到3-氰基-1,2,4-三氮唑
  参考文献：
  名称：

  等位利巴韦林类似物：合成和抗病毒活性

  摘要：

  通过两种不同的方式合成了新型的等位性利巴韦林类似物。其中一些对丙型肝炎病毒（HCV），单纯疱疹（HCV-1）和A型流感病毒显示了与病毒唑本身相当的抗病毒作用。获得的数据证实了与生物等位基因有关的利巴韦林可能的抗病毒活性机制的理论建议。

  DOI：

  10.1016/j.bmcl.2017.11.029
• 作为试剂：
  描述：

  在 三乙胺 、 3-氰基-1,2,4-三氮唑 作用下， 以 1,2-二氯乙烷 为溶剂， 以87.3 %的产率得到
  参考文献：
  名称：

  CN115784949

  摘要：

  公开号：

文献信息

• [EN] SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME<br/>[FR] INHIBITEURS SÉLECTIFS DE L'INFLAMMASOME NLRP3
  申请人：NODTHERA LTD

  公开号：WO2019025467A1

  公开（公告）日：2019-02-07

  The present disclosure relates to compounds of Formula (I): (I); and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as autoinflammatory and autoimmune diseases and cancers.

  本公开涉及式(I)化合物：(I)；及其药用可接受盐、药物组合物、使用方法和制备方法。所公开的化合物可用于通过抑制炎症小体来抑制IL-1家族细胞因子的成熟，并可用于治疗炎症小体活性涉及的疾病，如自炎性和自身免疫疾病以及癌症。
• [EN] CHEMICAL COMPOUNDS<br/>[FR] COMPOSÉS CHIMIQUES
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2019053617A1

  公开（公告）日：2019-03-21

  The invention is directed to substituted salicylamide derivatives. Specifically, the invention is directed to compounds according to FormµLa (I): wherein R, R1,P, X, Y, and Z are as defined herein; or a pharmaceutically acceptable salt thereof. The compounds of the invention are inhibitors of CD73 and can be usefµL in the treatment of cancer, pre-cancerous syndromes and diseases associated with CD73 inhibition, such as AIDS, the treatment of HIV, autoimmune diseases, infections, atherosclerosis, and ischemia–reperfusion injury. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting CD73 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  本发明涉及取代水杨酰胺衍生物。具体而言，本发明涉及式I化合物：其中R，R1，P，X，Y和Z定义如本文中；或其药用可接受盐。本发明的化合物是CD73的抑制剂，可用于治疗癌症、前癌症综合症以及与CD73抑制相关的疾病，例如艾滋病、治疗HIV、自身免疫疾病、感染、动脉粥样硬化和缺血再灌注损伤。因此，本发明进一步涉及包含本发明化合物的药物组合物。本发明进一步涉及使用本发明化合物或包含本发明化合物的药物组合物抑制CD73活性和治疗相关疾病的方法。
• 6,5-HETEROCYCLIC PROPARGYLIC ALCOHOL COMPOUNDS AND USES THEREFOR
  申请人：Staben Steven

  公开号：US20120214762A1

  公开（公告）日：2012-08-23

  The invention relates to novel compounds of Formula I: wherein A, Y, R 1 , R 2 and the subscript b each has the meaning as described herein and compounds of Formula I, and stereoisomers, geometric isomers, tautomers, solvates, metabolites, isotopes, pharmaceutically acceptable salts, or prodrugs thereof. Compounds of Formula I and pharmaceutical compositions thereof are useful in the treatment of disease and disorders in which undesired or over-activation of NF-kB signaling is observed.

  这项发明涉及公式I的新化合物： 其中A、Y、R1、R2和下标b各自具有如本文所述的含义，以及公式I的化合物、立体异构体、几何异构体、互变异构体、溶剂合物、代谢物、同位素、药学上可接受的盐或其前药。公式I的化合物及其药物组成物在治疗观察到NF-kB信号通路的不良或过度激活的疾病和紊乱中是有用的。
• [EN] DIKETOPIPERIDINE DERIVATIVES AS HIV ATTACHMENT INHIBITORS<br/>[FR] DÉRIVÉS DE LA DICÉTOPIPÉRIDINE UTILISÉS COMME INHIBITEURS DE FIXATION DU VIH
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2009158396A1

  公开（公告）日：2009-12-30

  Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, diketopiperidine derivatives that possess unique antiviral activity are provided. These compounds are useful for the treatment of HIV and AIDS.

  具有药物和生物影响特性的化合物，其药物组合物和使用方法已经列出。具体来说，提供了具有独特抗病毒活性的二酮哌啶衍生物。这些化合物对治疗艾滋病毒和艾滋病非常有用。
• 二氢嘧啶类化合物及其在药物中的应用
  申请人：广东东阳光药业有限公司

  公开号：CN103664897B

  公开（公告）日：2018-04-03

  本发明涉及一种二氢嘧啶类化合物及其作为药物的用途，尤其是作为用于治疗和预防乙型肝炎的药物的应用。具体地说，本发明涉及通式(I)或(Ia)所示的化合物或它们的对映异构体、非对映异构体、互变异构体、水合物、溶剂化物或药学上可接受的盐，其中各变量如说明书所定义。本发明还涉及通式(I)或(Ia)所示的化合物或它们的对映异构体、非对映异构体、互变异构体、水合物、溶剂化物或药学上可接受的盐或其药物组合物的用途，尤其是作为用于治疗和预防乙型肝炎的药物的用途。